US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Johnson & Johnson (NY:JNJ)

256.03 -2.63 (-1.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way. ↗
Rising interest rates are unlikely to change the dynamics in the healthcare sector, where people are willing to pay for care. 
Via The Motley Fool
Topics Economy
News headline image
The Stock Market Just Flashed a Warning Signal Seen Only Twice in 155 Years. Here Are 3 Stocks That Can Weather What History Says Comes Next. ↗
These stocks should hold up well no matter what the future holds for the overall market. 
Via The Motley Fool
Friday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
3 of the Best ETFs to Buy and Hold if a Recession Is Coming ↗
VHT, BND, and VOO could be your best bets in the next economic downturn. 
Via The Motley Fool
Topics ETFs Economy Regulatory Compliance
What's going on in today's session: dow jones movers ↗
Via Chartmill
News headline image
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? ↗
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks. 
Via The Motley Fool
News headline image
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale ↗
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years. 
Via The Motley Fool
These dow jones stocks are moving in today's session ↗
Via Chartmill
News headline image
Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue ↗
Jabil posted a double-beat quarter with nearly 29% revenue growth and 34% EPS growth, driven by AI demand, while maintaining buybacks and a Buy-rated analyst consensus. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
From Johnson & Johnson
Via Business Wire
News headline image
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. ↗
Medtronic is following a strategy that has worked well for Johnson & Johnson. 
Via The Motley Fool
News headline image
Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer. ↗
Analysts think this beaten-down healthcare stock will rebound. 
Via The Motley Fool
Topics Earnings
News headline image
If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's This ↗
New investors might be eager to jump in during a bull market. 
Via The Motley Fool
News headline image
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High ↗
This is not an exhaustive list. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Healthcare Dividend Stocks Offering More Than Just Income ↗
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027. 
Via MarketBeat
News headline image
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. ↗
SHCD is missing some of the healthiest dividend stocks. 
Via The Motley Fool
Topics ETFs Stocks
Which dow jones stocks are moving on Tuesday? ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Friday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Thursday. ↗
Via Chartmill
Thursday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
Bear Markets May Feel Frightening, But Here's How You Can Come Out Ahead ↗
The next bear market may be your best opportunity to grow your portfolio. 
Via The Motley Fool
Topics Economy
News headline image
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting? ↗
Wall Street thinks that this robotic surgical systems leader's sell-off is overdone. 
Via The Motley Fool
Topics Earnings
News headline image
2 Stocks to Buy Hand Over Fist if a Stock Market Crash Is Coming ↗
You can take these companies' dividends straight to the bank. 
Via The Motley Fool
Topics Economy
News headline image
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
From DePuy Synthes
Via Business Wire
News headline image
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal ↗
Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >